Illumina faces a difficult decision now that the US FTC has formally rejected its attempt to re-acquire Grail, the sequencing company it originally sold in 2016. The FTC and European regulators say the merger would stifle competition but the company plans to appeal the ruling.

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.